SCHEMBL30422501

SCHEMBL30422501

CCOc1ncncc1C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ PARP10 Q53GL7 1/20 0.40
▸ SIRT3 Q9NTG7 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ TSHR P16473 2/20 0.38
▸ NNMT P40261 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ RPS6KB1 P23443 2/20 0.35
▸ AKT1 P31749 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ SYK P43405 1/20 0.35
▸ MAPK1 P28482 2/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27185528 0.84 KMT2A (0.42) TSHRL3MBTL1ALDH1A1KDM4EMEN1
SCHEMBL30421542 0.84 KMT2A (0.42) TSHRL3MBTL1ALDH1A1KDM4EMEN1
SCHEMBL4501636 0.82 MKNK1 (0.46) MKNK1MKNK2L3MBTL1RPS6KB1MAPK1
SCHEMBL31582882 0.82 NNMT (0.45) MKNK1MKNK2SIRT3TDP1NNMT
SCHEMBL30509874 0.82 NNMT (0.45) MKNK1MKNK2SIRT3TDP1NNMT
SCHEMBL23143261 0.81 TSHR (0.46) TSHRL3MBTL1ALDH1A1MAPK1KDM4E
SCHEMBL31148366 0.81 TSHR (0.46) TSHRL3MBTL1ALDH1A1MAPK1KDM4E
SCHEMBL21128314 0.81 ALDH1A1 (0.42) TDP1TSHRL3MBTL1ALDH1A1MAPK1
SCHEMBL30962756 0.73 NNMT (0.40) MKNK1MKNK2PARP10TSHRNNMT
SCHEMBL6621875 0.73 MKNK1 (0.43) MKNK1MKNK2PARP10SIRT3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 — — EP disclosed
US-20250122192-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
EP-4441042-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME Rgenta Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
WO-2023102231-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122192-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME RTCB, NSUN2, PRPF19 MKNK1 3866/4885MKNK2 3715/4885PARP10 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback